Speaker: Christoph Röllig

0:01:31

Christoph Röllig on AML research in Dresden, Germany

0:01:42

AML: new targeted inhibitors as single agents?

0:00:53

The importance of using novel strategies to target leukemic stem cells more effectively

0:02:39

Results from the randomized Phase III DaunoDouble trial

0:02:47

Time to treatment doesn't impact outcome in intensively treated newly diagnosed AML

0:01:45

MRD detection techniques in AML: pros and cons

0:04:43

Treatment of NPM1-mutated AML: intensive standard treatment

0:01:29

Risk-adapted therapy of AML

0:01:45

HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial

0:03:26

Major AML treatment landscape changes

0:03:41

SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML

0:11:42

AML treatment: what does the data say?

0:01:17

Combination therapy for the treatment of AML

0:01:39

Optimizing chemotherapy in AML

0:01:42

Novel treatment combinations in AML: what’s to come?

0:01:38

Managing AML in elderly patients

0:02:05

Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML

0:01:26

Emerging management options for AML

0:03:42

Midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML

0:01:25

Factors that contribute to treatment decisions in acute myeloid leukemia

0:01:41

Applying the right therapies to the right AML patient population

0:05:41

Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia

0:02:08

The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigation

0:01:56

Immunotherapies for the treatment of AML